Cheryl McDonald, MD
Infectious Disease · Fort Worth, TXNPI 1013982511
Payments from drug & device makers
Across 1,238 payments — averaging $2500.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.9M
- Gilead$584K
- Viiv Healthcare Company$407K
- Janssen Research & Development, LLC$83K
- GSK$80K
- Pfizer$54K
- plus $34K from 28 others
Across 9 payments — averaging $106.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$960
What the payments were for
- Consulting fees$14,2948%
- Speaking & faculty fees$130,28873%
- Travel & lodging$17,70210%
- Food & beverage$16,1649%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 276 | $1,854,070 |
| Gilead | 324 | $583,606 |
| Viiv Healthcare Company | 221 | $407,117 |
| Janssen Research & Development, LLC | 23 | $83,355 |
| GSK | 23 | $79,501 |
| Pfizer | 18 | $54,028 |
| Insmed, Inc. | 108 | $15,195 |
| AbbVie | 29 | $14,036 |
| Theratechnologies Inc. | 25 | $1,075 |
| EMD Serono, Inc. | 42 | $727 |
| Cumberland Pharmaceuticals, Inc. | 13 | $648 |
| Shionogi Inc | 25 | $510 |
| Johnson & Johnson | 29 | $490 |
| Paratek Pharmaceuticals, Inc. | 22 | $394 |
| Janssen Products, LP | 2 | $185 |
| Napo Pharmaceuticals Inc | 7 | $144 |
| Astellas Pharma US Inc | 7 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Ferring Pharmaceuticals Inc. | 7 | $113 |
| Aimmune Therapeutics, Inc. | 4 | $111 |
| Melinta Therapeutics, LLC | 5 | $95 |
| Grifols USA, LLC | 4 | $72 |
| La Jolla Pharmaceutical Company | 2 | $52 |
| Amgen | 2 | $49 |
| Mayne Pharma Commercial LLC | 2 | $49 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Octapharma USA, Inc. | 2 | $29 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $26 |
| Eurofins Viracor, LLC | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Convatec Inc. | 1 | $22 |
| Vyera Pharmaceuticals, LLC | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,096,093 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 384 | $1,582,352 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 187 | $797,501 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 50 | $772,797 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 180 | $696,692 |
| SerostimSomatropin | 29 | $566,457 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 41 | $232,517 |
| PrezcobixDarunavir/Cobicistat | 75 | $200,859 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 52 | $196,182 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $186,550 |
| TivicayDolutegravir Sodium | 65 | $184,696 |
| DovatoDolutegravir Sodium/Lamivudine | 49 | $148,647 |
| JulucaDolutegravir/Rilpivirine | 37 | $137,440 |
| Egrifta SvTesamorelin Acetate | 17 | $127,023 |
| IsentressRaltegravir Potassium | 41 | $80,097 |
| DescovyEmtricitabine/Tenofov Alafenam | 32 | $75,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $583,606 | $2,455,091603 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca | $407,117 | $1,167,476331 claims |
| Insmed, Inc.Arikayce | $15,195 | $772,79750 claims |
| EMD Serono, Inc.Serostim | $727 | $566,45729 claims |
| Janssen Products, LPSymtuza | $185 | $232,51741 claims |
| Johnson & JohnsonPrezcobix | $490 | $200,85975 claims |
| Theratechnologies Inc.Egrifta Sv | $1,075 | $127,02317 claims |
| MerckIsentress | $1,854,070 | $80,09741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Fort Worth
- Cedric SpakFort Worth$427K
- Catherine ColquittFort Worth$142K
- Gene VoskuhlSherman$69.5M
- Mezgebe BerheDallas$11M
- Eleftherios MylonakisHouston$6.4M
- Mamta JainDallas$3.7M
- Ogechika AlozieEl Paso$2.5M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.